Header

UZH-Logo

Maintenance Infos

Lower Risk of B1-to-pB3-Stage Migration in Crohn’s Disease Upon Immunosuppressive and Anti-TNF Treatment in the Swiss IBD Cohort Study


Cernoch, Patrick S; Fournier, Nicolas; Zeitz, Jonas; Scharl, Michael; Morell, Bernhard; Greuter, Thomas; Schreiner, Philipp; Misselwitz, Benjamin; Safroneeva, Ekaterina; Schoepfer, Alain M; Vavricka, Stephan R; Rogler, Gerhard; Biedermann, Luc (2019). Lower Risk of B1-to-pB3-Stage Migration in Crohn’s Disease Upon Immunosuppressive and Anti-TNF Treatment in the Swiss IBD Cohort Study. Digestive Diseases and Sciences:Epub ahead of print.

Abstract

Background
While the long-term evolution of disease behavior in Crohn’s disease has been well described in the pre-anti-TNF era, our knowledge thereon remains scarce after the introduction of anti-TNF.
Aims
Our investigation examined the long-term evolution of disease concerning Montreal classification’s B-stages over time in patients enrolled into the Swiss IBD Cohort Study between 2006 and 2017.
Methods
We analyzed prospectively collected SIBDCS data using a Markov model and multivariate testing for effects of treatment and other confounders on B-stage migration over time. The primary outcome was a transition in disease behavior from B1 to either B2 or pB3, or from B2 to pB3, respectively.
Results
The 10- and 15-year probability of remaining in B1 was 0.61 and 0.48, as opposed to a probability to migrate to B2 or B3 of 0.25 or 0.14, and 0.32 or 0.2, after 10 and 15 years, respectively. In multivariate testing, the hazard ratio for migrating from B1 to pB3 (HR 0.27) and from B2 to pB3 (HR 0.12) was lower in patients > 40 years compared to patients < 17 years. We found that immunosuppression (HR 0.38) and treatment with anti-TNF for > 1 year (HR 0.30) were associated with a decreased likelihood of transitioning from stage B1 to pB3.
Conclusions
While in the anti-TNF era most patients with Crohn’s disease will eventually develop stricturing and/or penetrating complications, our data indicate that immunosuppressive and anti-TNF treatment for more than 1 year reduce the risk of transitioning from stage B1 to pB3 in the long-term run.

Abstract

Background
While the long-term evolution of disease behavior in Crohn’s disease has been well described in the pre-anti-TNF era, our knowledge thereon remains scarce after the introduction of anti-TNF.
Aims
Our investigation examined the long-term evolution of disease concerning Montreal classification’s B-stages over time in patients enrolled into the Swiss IBD Cohort Study between 2006 and 2017.
Methods
We analyzed prospectively collected SIBDCS data using a Markov model and multivariate testing for effects of treatment and other confounders on B-stage migration over time. The primary outcome was a transition in disease behavior from B1 to either B2 or pB3, or from B2 to pB3, respectively.
Results
The 10- and 15-year probability of remaining in B1 was 0.61 and 0.48, as opposed to a probability to migrate to B2 or B3 of 0.25 or 0.14, and 0.32 or 0.2, after 10 and 15 years, respectively. In multivariate testing, the hazard ratio for migrating from B1 to pB3 (HR 0.27) and from B2 to pB3 (HR 0.12) was lower in patients > 40 years compared to patients < 17 years. We found that immunosuppression (HR 0.38) and treatment with anti-TNF for > 1 year (HR 0.30) were associated with a decreased likelihood of transitioning from stage B1 to pB3.
Conclusions
While in the anti-TNF era most patients with Crohn’s disease will eventually develop stricturing and/or penetrating complications, our data indicate that immunosuppressive and anti-TNF treatment for more than 1 year reduce the risk of transitioning from stage B1 to pB3 in the long-term run.

Statistics

Citations

Altmetrics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Children's Hospital Zurich > Medical Clinic
04 Faculty of Medicine > University Hospital Zurich > Clinic for Gastroenterology and Hepatology
Dewey Decimal Classification:610 Medicine & health
Uncontrolled Keywords:Gastroenterology, Physiology
Language:English
Date:3 December 2019
Deposited On:10 Jan 2020 14:02
Last Modified:07 Feb 2020 08:49
Publisher:Springer
ISSN:0163-2116
OA Status:Closed
Publisher DOI:https://doi.org/10.1007/s10620-019-05978-9
PubMed ID:31797187

Download

Full text not available from this repository.
View at publisher

Get full-text in a library